Bull Horn Holdings Corp.: directors' dealings · United States · SEC (Form 4)

About Bull Horn Holdings Corp.

Bull Horn Holdings Corp. was originally a U.S.-listed SPAC, i.e. a special purpose acquisition company formed to complete a business combination rather than to run a conventional operating business. Public SEC materials and market references show that the company was listed on Nasdaq, with securities traded under symbols such as BHSE and BHSE.U before the post-merger transition. For international investors, the key point is that Bull Horn functioned as a capital-raising shell designed to acquire a target company in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1759186/000121390022020473/ea158593ex99-1_bullhorn.htm?utm_source=openai)) Historically, the company was created under the SPAC model and organized to pursue a merger with an operating business. SEC filings state that Bull Horn was formed to effect a business combination, which is the defining feature of this structure. That transaction was ultimately completed with Coeptis Therapeutics, after which Bull Horn changed its corporate name to Coeptis Therapeutics Holdings, Inc. Accordingly, Bull Horn should be viewed as the pre-closing public vehicle that enabled the combination, not as a standalone industrial or commercial enterprise with a broad operating history. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1759186/000121390022055315/fs42022a4ex3-2_bullhorn.htm?utm_source=openai)) From an activity standpoint, Bull Horn did not have a traditional portfolio of products, recurring services, or manufacturing operations. Its core business was financial and transactional: raise capital, remain publicly listed, and identify an acquisition target that could be taken public through a merger. In practice, the company’s economic relevance was tied to the execution of its business combination with Coeptis Therapeutics, a biopharmaceutical and technology company. That means the proper analytical lens is transaction analysis, sponsor quality, and merger execution rather than operating margin analysis or product-line competitiveness. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1759186/000121390022037409/fs42022a1_bullhorn.htm?utm_source=openai)) In competitive terms, Bull Horn occupied the typical SPAC position in the U.S. market: its attractiveness to investors depended on the credibility of the sponsor team, its capital structure, and the market’s view of the prospective acquisition target. The company’s public profile was therefore not driven by market share or brand strength, but by its ability to source and close a compelling transaction. Available public sources place the company’s headquarters in Miami Beach, Florida, United States, and indicate a Nasdaq Capital Market listing. ([simplywall.st](https://simplywall.st/stocks/us/diversified-financials/nasdaq-bhse.u/bull-horn-holdings/information?utm_source=openai)) Recent corporate developments are material: Bull Horn completed its initial business combination with Coeptis Therapeutics on October 28, 2022, and the issuer subsequently operated under the Coeptis Therapeutics Holdings name. Later SEC and investor communications refer to Coeptis, not Bull Horn, confirming that the original Bull Horn identity was retired after the merger. For French-speaking investors, the practical takeaway is that Bull Horn Holdings Corp. was a U.S. Nasdaq-listed SPAC in the United States whose legacy is the transaction itself, while the operating story now belongs to the post-merger Coeptis platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1759186/000168316825008341/coeptis_i10q-093025.htm?utm_source=openai))